重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死的疗效及安全性

Recombinant Tissue-type Plasminogen Activator Thrombolytic Therapy of Acute Cerebral Infarction and Safety

目的观察临床应用重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓治疗急性脑梗死的疗效及安全性。方法选取2013年7月-2015年7月在我院进行诊治的66例急性脑梗死患者,按随机数字表法随机分为对照组和观察组各33例,对照组患者给予奥扎格雷钠氯化钠注射液,观察组给予rt-PA治疗,观察两组患者治疗后的临床疗效及不良反应发生情况。结果两组患者治疗后的临床治疗总有效率比较观察组明显高于对照组(P<0.05),而安全性比较无明显差异(P>0.05)。结论临床应用rt-PA静脉溶栓治疗急性脑梗死能明显提高治疗有效率,且安全性高,可在临床推广应用。

Objective To observe the clinical application of recombinant tissue plasminogen activator（rt-PA） clinical efficacy and safety of intravenous thrombolytic therapy for acute cerebral infarction. Methods 66 cases of patients with acute cerebral infarction in July 2013 -2015 year in July were treated in our hospital, were randomly divided into control group and observation group of 33 cases and the control group were treated with Sodium Ozagrel and Sodium Chloride Injection, the observation group was treated with rt-PA, to observe the clinical efficacy and adverse reactions of the two groups after treatment were observed. Results The clinical treatment of two groups of patients after total effective observation group was significantly higher（P〈0.05）, whereas no significant difference in safety（P0.05）. Conclusion The clinical application of rt-PA thrombolytic therapy of acute cerebral infarction can significantly improve treatment efficiency and safety can be applied in clinical practice.